Thymulin

What it is

Thymulin (also known as facteur thymique sérique or FTS) is a nine-amino-acid peptide originally isolated from thymic epithelium. Active thymulin requires zinc binding for biological activity (sometimes designated FTS-Zn). The peptide was identified in the 1970s during the era of intense interest in thymic peptides as immune-modulating therapeutics.

Thymulin has not received FDA approval for any indication. Most research has been in immunology and animal models. Clinical use in humans is very limited and primarily research-based.

Mechanism of action

Thymulin appears to modulate T-cell function and differentiation, with effects somewhat overlapping with thymosin alpha-1 but generally less well-characterized. The zinc-dependent activity is a notable feature — the peptide is essentially inactive without zinc binding.

Clinical evidence

The clinical research base on thymulin is limited compared to thymosin alpha-1. Some early clinical interest in autoimmune diseases and immune deficiency states did not translate into established clinical applications. Modern research interest in this peptide is modest.

Why we don’t prescribe it at The Tide

For immune modulation indications, thymosin alpha-1 has substantially more clinical evidence and decades of established international use. Thymulin’s evidence base does not support clinical use over thymosin alpha-1 for any specific indication. Patients with immune dysregulation needs are better served by thymosin alpha-1 protocols.

Side effects and contraindications

Limited human safety data. Theoretical caution in autoimmune conditions, malignancy, organ transplant patients on immunosuppression, and pregnancy. We do not have the experience base to provide detailed clinical guidance on this peptide.